These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21961995)

  • 1. Effects of ethinyl estradiol-cyproterone acetate treatment on metabolic syndrome, fat distribution and carotid intima media thickness in polycystic ovary syndrome.
    Karabulut A; Demirlenk S; Sevket O
    Gynecol Endocrinol; 2012 Apr; 28(4):245-8. PubMed ID: 21961995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral contraception vs insulin sensitization for 18 months in nonobese adolescents with androgen excess: posttreatment differences in C-reactive protein, intima-media thickness, visceral adiposity, insulin sensitivity, and menstrual regularity.
    Ibáñez L; Díaz M; Sebastiani G; Marcos MV; López-Bermejo A; de Zegher F
    J Clin Endocrinol Metab; 2013 May; 98(5):E902-7. PubMed ID: 23547047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome.
    Gul OB; Somunkiran A; Yucel O; Demirci F; Ozdemir I
    Arch Gynecol Obstet; 2008 Jan; 277(1):25-30. PubMed ID: 17618446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ethinylestradiol/cyproterone acetate on endothelial function in young non-obese women with polycystic ovary syndrome: a pilot study.
    Naka KK; Kalantaridou SN; Bechlioulis A; Kravariti M; Kazakos N; Katsouras CS; Tsatsoulis A; Michalis LK
    Gynecol Endocrinol; 2011 Sep; 27(9):615-21. PubMed ID: 21329419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
    J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ethinyl estradiol-cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome.
    Karakurt F; Carlioglu A; Kaygusuz I; Gumus II; Uz B; Akdeniz D
    Arch Gynecol Obstet; 2014 Jan; 289(1):135-40. PubMed ID: 23880889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?
    Kabil Kucur S; Gozukara I; Aksoy A; Uludag EU; Keskin H; Kamalak Z; Carlioglu A
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):862-5. PubMed ID: 25402193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome.
    Kebapcilar L; Taner CE; Kebapcilar AG; Alacacioglu A; Sari I
    Arch Gynecol Obstet; 2010 Jan; 281(1):35-42. PubMed ID: 19330342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome.
    Mhao NS; Al-Hilli AS; Hadi NR; Jamil DA; Al-Aubaidy HA
    Diabetes Metab Syndr; 2016; 10(1 Suppl 1):S95-8. PubMed ID: 26703220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of androgen excess in adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin.
    Ibáñez L; Diaz M; Sebastiani G; Sánchez-Infantes D; Salvador C; Lopez-Bermejo A; de Zegher F
    J Clin Endocrinol Metab; 2011 Nov; 96(11):3361-6. PubMed ID: 21865363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome.
    Sabuncu T; Harma M; Harma M; Nazligul Y; Kilic F
    Fertil Steril; 2003 Nov; 80(5):1199-204. PubMed ID: 14607575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study.
    Karakurt F; Sahin I; Güler S; Demirbas B; Culha C; Serter R; Aral Y; Bavbek N
    Adv Ther; 2008 Apr; 25(4):321-8. PubMed ID: 18389188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol-cyproterone acetate.
    Gode F; Karagoz C; Posaci C; Saatli B; Uysal D; Secil M; Akdeniz B
    Arch Gynecol Obstet; 2011 Oct; 284(4):923-9. PubMed ID: 21140159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy].
    Orbetsova M; Kamenov Z; Kolarov G; Zakharieva S; Khristov V; Atanasova I; Shigarminova R; Milcheva B; Genchev G
    Akush Ginekol (Sofiia); 2006; 45(7):16-28. PubMed ID: 17489164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
    Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Sanchón R; San Millán JL; Escobar-Morreale HF
    Diabetes Care; 2007 Sep; 30(9):2309-13. PubMed ID: 17536071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
    Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Martínez-Bermejo E; Lasunción MA; Escobar-Morreale HF
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.
    Lemay A; Dodin S; Turcot L; Déchêne F; Forest JC
    Hum Reprod; 2006 Jan; 21(1):121-8. PubMed ID: 16199428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of ethinyl estradiol and desogestrel on clinical and metabolic parameters in Indian patients with polycystic ovary syndrome.
    Bhattacharya SM; Ghosh M; Basu R
    J Obstet Gynaecol Res; 2012 Jan; 38(1):285-90. PubMed ID: 22070369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.